N. Deb

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

R. Levy, M. Goris, R. Negrin, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

TARGIT-R (Retrospective): North American Experience with Intraoperative Radiation Using Low-Kilovoltage X-Rays for Breast Cancer

B. Rosen, W. Small, A. Fyles, 2016, Annals of Surgical Oncology.

TARGIT-R (Retrospective): 5-Year Follow-Up Evaluation of Intraoperative Radiation Therapy (IORT) for Breast Cancer Performed in North America

W. Small, C. Shah, A. Fyles, 2021, Annals of Surgical Oncology.

High-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.

M. Mehta, B. Fisher, H. Shu, 2016, International journal of radiation oncology, biology, physics.

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Arif N Ali, J. Villano, J. Raizer, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.

M. Goris, M. Becker, S. Knox, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

High-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.

H. Shu, M. Vogelbaum, Y. Kwok, 2016, International journal of radiation oncology, biology, physics.

Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539.

H. Shu, J. D. de Groot, M. Vogelbaum, 2022, Neuro-oncology.